Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study

J Antimicrob Chemother. 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. Epub 2015 Apr 26.
No abstract available

Keywords: NNRTIs; NRTIs; PI-sparing strategies.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / pharmacokinetics*
  • Chromatography, Liquid
  • Cyclohexanes / administration & dosage
  • Cyclohexanes / pharmacokinetics*
  • Drug Therapy, Combination / methods
  • Female
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Maraviroc
  • Middle Aged
  • Plasma / chemistry*
  • Raltegravir Potassium / administration & dosage
  • Raltegravir Potassium / pharmacokinetics*
  • Tandem Mass Spectrometry
  • Triazoles / administration & dosage
  • Triazoles / pharmacokinetics*

Substances

  • Anti-HIV Agents
  • Cyclohexanes
  • Triazoles
  • Raltegravir Potassium
  • Maraviroc